Search Results - "Makhson, A"

Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer by Green, M. R., Manikhas, G. M., Orlov, S., Afanasyev, B., Makhson, A. M., Bhar, P., Hawkins, M. J.

“…Background: Abraxane® (ABI-007) is a novel 130-nm, albumin-bound (nab™) particle form of paclitaxel designed to utilize endogenous albumin pathways to increase…”
Get full text

Development of a new G-CSF product based on biosimilarity assessment by Gascon, P., Fuhr, U., Sörgel, F., Kinzig-Schippers, M., Makhson, A., Balser, S., Einmahl, S., Muenzberg, M.

“…Zarzio®, a new recombinant human granulocyte colony-stimulating factor (filgrastim), was evaluated in healthy volunteers and neutropenic patients in phase I…”
Get full text

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer by Scagliotti, Giorgio V, Germonpré, Paul, Bosquée, Leon, Vansteenkiste, Johan, Gervais, R, Planchard, David, Reck, Martin, De Marinis, Filippo, Lee, Jin Soo, Park, Keunchil, Biesma, Bonne, Gans, Steven, Ramlau, R, Szczesna, Aleusandra, Makhson, A, Manikhas, G, Morgan, Bruno, Zhu, Y, Chan, Kai C, von Pawel, Joachim

“…Abstract Background This is a phase II randomized study to evaluate the efficacy and safety of bortezomib and pemetrexed alone or in combination, in patients…”
Get full text

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients by Guan, Z, Xu, B, DeSilvio, M, Newstat, B, Moore, Y, Makhson, A

Get full text

Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC) by Bergh, J., Greil, R., Voytko, N., Makhson, A., Cortes, J., Lortholary, A., Huang, X., Giorgetti, C., Kern, K. A., Lichinitser, M.

“…Abstract only LBA1010 Background: Taxane-based chemotherapy (CT) improves progression-free survival (PFS) in patients (pts) with newly diagnosed HER2-negative…”
Get full text

Expression of Matrix Metalloproteinases 1, 2, 9 and Their Tissue Inhibitor-1 in Cartilage-Forming Osteal Tumors by Boulytcheva, I. V, Kushlinskii, N. E, Dvorova, E. K, Kazachok, I. V, Makhson, A. N

“…The expression of MMP-1, -2, -9 and TIMP-1 was studied in 10 benign cartilage-forming osteal tumors (5 osteochondromas and 5 chondromas) and 39 chondrosarcomas…”
Get full text

Extralesional resection for tumours of the pelvic bones by Makhson, A

“…A retrospective analysis of 92 patients with tumours of the bony pelvis is presented. Limbsparing operations may be adequate or inadequate. Adequate operations…”
Get full text

THE EFFECT OF SAMPLING TECHNIQUE ON BACTERIOLOGICAL RESULTS IN PATIENTS WITH MALIGNANT LUNG TUMORS by A. N. JACOT, D. V. SOKOLOV, S. D. MITROKHIN, V. V. SHEVTSOV, V. V. SOKOLOV, B. S. LENSKY, A. N. MAKHSON

“…Purpose of the study: to evaluate the lower respiratory tract microflora in patients with malignant lung tumors with chronic obstructive pulmonary disease…”
Get full text

LONG-TERM TREATMENT RESULTS OF BONE SARCOMA PATIENTS WITH CONSIDERATION OF SERUM METALLOPROTEINASE LEVELS by Babkina, I. V., Bondarev, A. V., Shchupak, M. Yu, Boulytcheva, I. V., Soloviev, Yu. N., Makhson, A. N., Aliev, M. D., Kushlinskii, N. E.

“…Background: Bone sarcomas are extremely malignant prone to rapid hematogenic metastasing. Evaluation of biological marker expression by the tumor is important…”
Get full text

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC) by Gradishar, W, Krasnojon, D, Cheporov, S, Makhson, A, Manikhas, G, Clawson, A, Bhar, P

Get full text

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS by Bokemeyer, C, Staroslawska, E, Makhson, A, Bondarenko, I, Hartmann, J.T, Shelygin, Y, Kolesnik, O, Volovat, C, Zubel, A, Koralewski, P

Get full text

8064 Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer by Bidzinski, M, Poveda, A, Vermorken, J, Kaye, S, Makhson, A, Jagiello-Gruszfeld, A, Poole, C, Gomez, J, Parekh, T, Monk, B

Get full text

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer by Gradishar, W.J, Krasnojon, D, Cheporov, S, Makhson, A, Georgy, M, Clawson, A, Hawkins, M.J

Get full text

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer by Hawkins, M.J, Georgy, M, Makhson, A, Cheporov, S, Sergey, O, Yablonsky, P, Bhar, P, Socinski, M.A

Get full text

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study by LEYLAND-JONES, Brian, SEMIGLAZOV, Vladimir, BIAKHOV, Mikhail, VALUCKAS, Konstantinas, VOZNYI, Edouard, XIANGYANG LIU, VERCAMMEN, Els, PAWLICKI, Marek, PIENKOWSKI, Tadeusz, TJULANDIN, Sergei, MANIKHAS, George, MAKHSON, Antoly, ROTH, Anton, DODWELL, David, BASELGA, Jose

“…To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in women…”
Get full text

Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study by Wimberger, P, Burges, A, Gorbounova, V, Sommer, H, Schmalfeldt, B, Pfisterer, J, Lichinitser, M, Makhson, A, Ströhlein, M, Eiermann, W, Biakhov, M, Moiseenko, V, Bois, A du, Kimmig, R

Get full text

Soft tissue chondroma by Bulycheva, I V, Makhson, A N, Kuz'min, I V, Denisov, K A

“…The paper gives a rare case of soft tissue chondroma in a 55-year-old female woman who has unsuccessfully received physiotherapeutic procedures for more than 6…”
Get more information

Abstract P4-12-08: Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) by Martín, M, Makhson, A, Gligorov, J, Lichinitser, M, Lluch, A, Semiglazov, V, de Ducla, S, Mitchell, L, Tjulandin, S

“…Abstract Background: After median follow-up of 8.8 months, the primary efficacy results from the HAX study [Martín et al., Oncologist 2012] demonstrated a 73%…”
Get full text

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer by Baselga, José, Zambetti, Milvia, Llombart-Cussac, Antoni, Manikhas, Georgy, Kubista, Ernst, Steger, Günther G, Makhson, Anatoly, Tjulandin, Sergei, Ludwig, Heinz, Verrill, Mark, Ciruelos, Eva, Egyhazi, Suzanne, Xu, Li-An, Zerba, Kim E, Lee, Hyerim, Clark, Edwin, Galbraith, Susan

“…This phase II study evaluated the efficacy and safety of ixabepilone as neoadjuvant therapy for invasive breast cancer not amenable to breast conservation…”
Get full text

Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1 by Yardley, D, Hurvitz, S, Jiang, Z-f, Toi, M, Burris, H, Buyse, M, Slamon, D, Makhson, A, Elsaid, A, Lerzo, G, Hellerstedt, B, Nuzzo, F, Sohn, J, Manzyuk, L, Cabaribere, D, Lincy, J, Weimann, A, Noel-Baron, F, Pacaud, L, Andre, F

“…Abstract Background Everolimus (EVE), an mTOR inhibitor has shown activity in HER2+ advanced breast cancer (ABC) in both preclinical and clinical studies. In…”
Get full text